Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Long-Term Liabilities - Components of Accrued Expenses and Other Long-Term Liabilities (Detail)

v3.8.0.1
Accrued Expenses and Other Long-Term Liabilities - Components of Accrued Expenses and Other Long-Term Liabilities (Detail) - USD ($)
$ in Thousands
Sep. 30, 2017
Dec. 31, 2016
Accrued expenses:    
Professional fees $ 1,297 $ 1,253
Salaries, bonuses and related benefits 4,178 2,846
Accrued Severance 0 53
Accrued Legal Settlement [1] 2,212 0
Ovamed manufacturing rights - short term component 0 900
Research and development 3,311 394
Dr. Falk Pharma milestone 2,950 2,634
Other 2,703 2,002
Total accrued expenses 16,651 10,082
Other long-term liabilities:    
Deferred rent and long-term lease abandonment charge 4,736 5,014
Total other long-term liabilities $ 4,736 $ 5,014
[1] In connection with a legal settlement (see Note 16), the Company is required to deliver 200,000 Mustang common shares, held by the Company, to the Plaintiff. At September 30, 2017, the Company recorded, this settlement as an accrued, since in accordance with ASC 450 – Contingencies, the transfer of the consideration was probable. As such the Company recorded an accrued expense of $2.0 million representing the value of the shares transferred.